 LEXINGTON, Mass., Feb. 26, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC, a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief... 